Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.
There is an urgent need for novel biomarkers that can be used to improve the diagnosis, predict the disease progression, improve our understanding of the pathology or serve as therapeutic targets for neurodegenerative diseases. Cerebrospinal fluid (CSF) is in direct contact with the CNS and reflects the biochemical state of the CNS under different physiological and pathological settings. Because of this, CSF is regarded as an excellent source for identifying biomarkers for neurological diseases and other diseases affecting the CNS. Quantitative proteomics and sophisticated computational software applied to analyze the protein content of CSF has been fronted as an attractive approach to find novel biomarkers for neurological diseases. This review will focus on some of the potential pitfalls in biomarker studies using CSF, summarize the status of the field of CSF proteomics in general, and discuss some of the most promising proteomics biomarker study approaches. A brief status of the biomarker discovery efforts in multiple sclerosis, Alzheimer's disease, and Parkinson's disease is also given.
Institute of Medicine, University of Bergen, Bergen, Norway.
A C
AC
Kroksveen
J A
JA
Opsahl
T T
TT
Aye
R J
RJ
Ulvik
F S
FS
Berven
D000818:Animals; D015415:Biomarkers / Q000032:analysis / Q000097:blood / Q000134:cerebrospinal fluid*; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis* / Q000378:metabolism; D016000:Cluster Analysis; D056726:Genetic Association Studies / Q000379:methods; D006801:Humans; D019636:Neurodegenerative Diseases / Q000134:cerebrospinal fluid* / Q000175:diagnosis* / Q000378:metabolism; D040901:Proteomics / Q000379:methods*; D054928:Validation Studies as Topic
D015415:Biomarkers; D002556:Cerebrospinal Fluid Proteins